Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

503 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865).
Newling DW, Fossa SD, Tunn UW, Kurth KH, de Pauw M, Sylvester R. Newling DW, et al. Among authors: sylvester r. J Urol. 1993 Dec;150(6):1840-4. doi: 10.1016/s0022-5347(17)35911-6. J Urol. 1993. PMID: 8230517 Clinical Trial.
Comparison of the effects of high dose Estramustine phosphate and mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine-independent prostatic cancer: an interim analysis of EORTC-GU Group study no. 30865.
Newling DW, Fossa S, Tunn U, Kurth KH, De Pauw M, Sylvester R. Newling DW, et al. Among authors: sylvester r. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):971-5. doi: 10.1016/0960-0760(90)90452-q. J Steroid Biochem Mol Biol. 1990. PMID: 2126739 Clinical Trial.
Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R. Pavone-Macaluso M, et al. Among authors: sylvester r. J Urol. 1986 Sep;136(3):624-31. doi: 10.1016/s0022-5347(17)44996-2. J Urol. 1986. PMID: 2942707 Clinical Trial.
Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group.
Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I, De Pauw M, Sylvester R. Newling DW, et al. Among authors: sylvester r. Eur Urol. 1995;27(2):110-6. doi: 10.1159/000475139. Eur Urol. 1995. PMID: 7744151 Clinical Trial.
Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group.
Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, Sylvester R. Bouffioux C, et al. Among authors: sylvester r. J Urol. 1995 Mar;153(3 Pt 2):934-41. J Urol. 1995. PMID: 7853578 Clinical Trial.
The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.
Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R. Robinson MR, et al. Among authors: sylvester r. Eur Urol. 1995;28(4):273-83. Eur Urol. 1995. PMID: 8575493 Clinical Trial.
Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.
Kurth K, Tunn U, Ay R, Schröder FH, Pavone-Macaluso M, Debruyne F, ten Kate F, de Pauw M, Sylvester R. Kurth K, et al. Among authors: sylvester r. J Urol. 1997 Aug;158(2):378-84. doi: 10.1016/s0022-5347(01)64484-7. J Urol. 1997. PMID: 9224307 Clinical Trial.
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group.
de Voogt HJ, Studer U, Schröder FH, Klijn JG, de Pauw M, Sylvester R. de Voogt HJ, et al. Among authors: sylvester r. Eur Urol. 1998;33(2):152-8. doi: 10.1159/000019547. Eur Urol. 1998. PMID: 9519356 Clinical Trial.
503 results